Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 15/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 15/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 1.00 |
| ▸ | KDM4A | O75164 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149258 | 0.83 | KDM5A (1.00) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16149595 | 0.83 | KDM4C (1.00) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL17695213 | 0.76 | KDM4C (0.62) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL17695216 | 0.76 | KDM4C (0.62) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16150698 | 0.75 | KDM4C (1.00) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL21204937 | 0.74 | KDM4C (0.64) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL21204889 | 0.74 | KDM4C (0.63) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL16157332 | 0.74 | KDM5A (1.00) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL17610154 | 0.73 | KDM4C (1.00) | KDM5AKDM5BKDM4CKDM4A | |
| SCHEMBL19605364 | 0.73 | KDM4C (0.62) | KDM5AKDM5BKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9873697-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738637-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738637-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-07-07 | — | — | US | disclosed |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-07-07 | — | — | US | disclosed |
| EP-2968282-A1 | HISTONE DEMENTHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164708-A1 | HISTONE DEMENTHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164708-A1 | HISTONE DEMENTHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM5A 3/4885KDM5B 6/4885KDM4C 12/4885 |
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM5B 2/4885KDM4C 23/4885 |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM5A 3/4885KDM5B 6/4885KDM4C 12/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM5B 2/4885KDM4C 23/4885 |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM5A 3/4885KDM5B 6/4885KDM4C 12/4885 |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM5A 3/4885KDM5B 6/4885KDM4C 12/4885 |
| US-10174026-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | KDM5A 3/4885KDM5B 6/4885KDM4C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.